Psychogenic movement disorders: A crisis for neurology Mark Hallett Invited Commentary Pages: 269 - 271
Tetrabenazine versus placebo for chorea in huntington’s disease John C. MorganKapil D. Sethi Clinical Trials Report Pages: 277 - 278
Ropinirole versus placebo in primary restless legs syndrome John C. MorganKapil D. Sethi Clinical Trials Report Pages: 278 - 280
Preclinical diagnosis of parkinson’s disease: Are we there yet? Andrew SiderowfMatthew B. Stern OriginalPaper Pages: 295 - 301
Impulse control disorders in parkinson’s disease Daniel WeintraubMarc N. Potenza OriginalPaper Pages: 302 - 306
Autoantibodies: A novel etiology for refractory epilepsy? Carl W. BazilLawrence J. Hirsch Clinical Trials Report Pages: 309 - 310
Antiepileptic therapy in patients with central nervous system malignancies Glen H. J. Stevens OriginalPaper Pages: 311 - 318
Cognitive functioning following epilepsy surgery Marla J. HambergerEvan B. Drake OriginalPaper Pages: 319 - 326
Magnetoencephalography in epilepsy: tailoring interpretation and making inferences Joshua CappellCatherine SchevonRonald G. Emerson OriginalPaper Pages: 327 - 331
State of the ketogenic diet(s) in epilepsy Jennifer HuffmanEric H. Kossoff OriginalPaper Pages: 332 - 340
Antiepileptic drugs and neurodevelopment Gholam K. MotamediKimford J. Meador OriginalPaper Pages: 341 - 346
Use of complementary and alternative medicine in epilepsy Valeria RicottiNorman Delanty OriginalPaper Pages: 347 - 353
